Abbott Laboratories Reports 7.8% Sales Increase but Declines in Net Earnings in Q1 2026

Abbott Laboratories reported a net sales increase of 7.8% for the first quarter of 2026, reaching $11.164 billion compared to $10.358 billion in the same period last year. The company's net earnings, however, decreased to $1.077 billion, or $0.61 per diluted share, down from $1.325 billion, or $0.76 per diluted share, in the prior year. This decline in profitability was attributed to higher costs associated with the acquisition of Exact Sciences, which Abbott completed on March 23, 2026, for approximately $20.6 billion, primarily funded through the issuance of long-term debt.

The financial performance reflects significant changes across Abbott's business segments. The Established Pharmaceutical Products segment saw a 13.2% increase in sales, while the Medical Devices segment also reported a 13.2% rise. In contrast, Nutritional Products experienced a 6.0% decline, primarily due to lower sales volumes in both pediatric and adult nutritional products. The Diagnostic Products segment benefited from the acquisition of Exact Sciences, contributing $96 million in sales since the acquisition date. Overall, the company’s gross profit margin slightly decreased to 52.4% from 52.8% in the previous year, impacted by rising costs and foreign exchange fluctuations.

Abbott's operational metrics indicate a strategic focus on growth through acquisitions and product innovation. The Exact Sciences acquisition is expected to enhance Abbott's position in the cancer diagnostics market, adding products like Cologuard® and Oncotype DX® to its portfolio. The company reported a total employee headcount of approximately 113,000 as of March 31, 2026, reflecting ongoing investments in talent and resources to support its expanding operations. Additionally, Abbott's cash and cash equivalents decreased to $6.803 billion from $8.522 billion at the end of 2025, largely due to cash outflows related to the acquisition and debt repayments.

Looking ahead, Abbott anticipates continued growth driven by its diversified product offerings and strategic acquisitions. The company expects to recognize approximately $6.2 billion in future revenue from unsatisfied performance obligations, primarily in the Diagnostic Products segment. Abbott's management remains optimistic about the integration of Exact Sciences and its potential to drive future sales growth, despite the challenges posed by market conditions and increased operational costs. The company has also declared a quarterly dividend of $0.63 per share, reflecting a 6.8% increase from the previous year, indicating confidence in its long-term financial health.